CX 801
Alternative Names: CX-801Latest Information Update: 16 Aug 2024
At a glance
- Originator CytomX Therapeutics
- Class Antineoplastics; Immunotherapies; Interferons; Recombinant fusion proteins
- Mechanism of Action Interferon alpha-2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 08 Aug 2024 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Combination therapy) in USA (Parenteral) (NCT06462794)
- 08 Aug 2024 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Monotherapy) in USA (Parenteral) (NCT06462794)
- 07 May 2024 CytomX Therapeutics and Merck enter a clinical trial collaboration and supply agreement for CX 801 in combination with Pembrolizumab for Solid tumours